Injectable magnesium oxychloride cement foam (mocf)-derived scaffold for treating osteoporotic bone defects
US-2024108785-A1 · Apr 4, 2024 · US
US12558454B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12558454-B2 |
| Application number | US-202418402953-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 3, 2024 |
| Priority date | Dec 12, 2014 |
| Publication date | Feb 24, 2026 |
| Grant date | Feb 24, 2026 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention includes compositions including magnesium-lithium alloys containing various alloying elements for medical implant devices. The devices are constructed of the compositions or have applied thereto a coating formed therefrom. Within the structure of the magnesium-lithium alloy, there is a co-existence of alpha and beta phases. The invention also includes methods of preparing the magnesium-lithium-based alloys and articles, such as medical implant devices, for use in medical applications, including orthopedic, dental, craniofacial and cardiovascular surgeries.
Opening claim text (preview).
The invention claimed is: 1 . A method for preparing a coated medical implant device, comprising: obtaining a substrate structured for implanting into a body; forming a coating composition comprising: forming an alloy, comprising: I alloying about 9.0% by weight of lithium, 0.96% by weight of zinc, and 0.01% by weight of aluminum, and a remainder of magnesium based on the total weight of the alloy, or II alloying about 8.99% by weight of lithium, 0.87% by weight zinc, and 1.07% by weight aluminum, and a remainder of magnesium based on the total weight of the alloy, or III alloying about 6.11% by weight of lithium, 0.92% by weight zinc, and 0.04% by weight aluminum, and a remainder of magnesium based on the total weight of the alloy, wherein the alloy of I, II or III is structured to exhibit a co-existence of alpha and beta phases, and wherein the alloy of I, II or III exhibits one or more of improved ductility and elasticity; and applying the coating composition onto a surface of the substrate to form a coating thereon. 2 . The method of claim 1 , wherein the alloying step further comprises adding to I, II or III one or more alloying elements selected from the group consisting of iron, zirconium, manganese, calcium, yttrium, rare earth elements, strontium, copper, silver, silicon, sodium, potassium, and cerium. 3 . The method of claim 1 , further comprising adding an active agent to the coating composition. 4 . The method of claim 1 , further comprising using the coated medical implant device in orthopedic, dental, craniofacial and cardiovascular surgeries. 5 . The method of claim 1 , wherein the coated medical implant device releases lithium ions as a therapeutic drug eluting device. 6 . The method of claim 1 , wherein the alloying step comprises: high energy mechanical alloying of I, II or III alloy compositions; followed by uniaxial or isostatic compaction; and followed by sintering.
Inorganic materials · CPC title
Other specific inorganic materials not covered by A61L31/084 or A61L31/086 · CPC title
Other specific inorganic materials not covered by A61L27/303 - A61L27/32 · CPC title
Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06 · CPC title
Metals or alloys · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.